Takeda Pharmaceutical Company Limited (4502.T)
JPY 4160.0
(2.34%)
JPY 4160.0
(2.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 214.07 Billion JPY | -18.2% |
| 2022 | 490.5 Billion JPY | 6.44% |
| 2021 | 460.84 Billion JPY | -9.51% |
| 2020 | 509.26 Billion JPY | 407.2% |
| 2019 | 100.4 Billion JPY | -51.01% |
| 2018 | 204.96 Billion JPY | -15.23% |
| 2017 | 241.78 Billion JPY | 55.13% |
| 2016 | 155.86 Billion JPY | 19.14% |
| 2015 | 130.82 Billion JPY | 201.22% |
| 2014 | -129.25 Billion JPY | -192.81% |
| 2013 | 139.27 Billion JPY | 13.69% |
| 2012 | 122.5 Billion JPY | -53.78% |
| 2011 | 265.02 Billion JPY | -27.8% |
| 2010 | 367.08 Billion JPY | -12.64% |
| 2009 | 420.21 Billion JPY | 37.11% |
| 2008 | 306.46 Billion JPY | -27.57% |
| 2007 | 423.12 Billion JPY | -7.72% |
| 2006 | 458.5 Billion JPY | 13.83% |
| 2005 | 402.8 Billion JPY | 4.55% |
| 2004 | 385.27 Billion JPY | 3.67% |
| 2003 | 371.63 Billion JPY | 19.62% |
| 2002 | 310.68 Billion JPY | 10.47% |
| 2001 | 281.24 Billion JPY | 24.39% |
| 2000 | 226.1 Billion JPY | 31.88% |
| 1999 | 171.44 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 195.46 Billion JPY | -16.14% |
| 2024 Q1 | 219.71 Billion JPY | 41044.57% |
| 2023 FY | 401.22 Billion JPY | -18.2% |
| 2023 Q1 | 168.57 Billion JPY | 90.34% |
| 2023 Q4 | 534 Million JPY | -99.49% |
| 2023 Q3 | 104.91 Billion JPY | 312.63% |
| 2023 Q2 | -49.34 Billion JPY | -129.27% |
| 2022 FY | 490.5 Billion JPY | 6.44% |
| 2022 Q1 | 150.51 Billion JPY | 9396.79% |
| 2022 Q2 | 104.43 Billion JPY | -30.61% |
| 2022 Q3 | 146.99 Billion JPY | 40.74% |
| 2022 Q4 | 88.56 Billion JPY | -39.75% |
| 2021 Q3 | 116.48 Billion JPY | 19.56% |
| 2021 FY | 460.84 Billion JPY | -9.51% |
| 2021 Q1 | 248.55 Billion JPY | 65.11% |
| 2021 Q2 | 97.42 Billion JPY | -60.8% |
| 2021 Q4 | -1.61 Billion JPY | -101.39% |
| 2020 FY | 509.26 Billion JPY | 407.2% |
| 2020 Q4 | 150.54 Billion JPY | 5.17% |
| 2020 Q1 | 167.28 Billion JPY | 369.22% |
| 2020 Q2 | 48.3 Billion JPY | -71.13% |
| 2020 Q3 | 143.14 Billion JPY | 196.34% |
| 2019 Q1 | 9.86 Billion JPY | 112.42% |
| 2019 FY | 100.4 Billion JPY | -51.01% |
| 2019 Q3 | 53.51 Billion JPY | 32.31% |
| 2019 Q2 | 40.44 Billion JPY | 309.93% |
| 2019 Q4 | -62.13 Billion JPY | -216.12% |
| 2018 Q4 | -79.45 Billion JPY | -170.65% |
| 2018 FY | 204.96 Billion JPY | -15.23% |
| 2018 Q2 | 73.08 Billion JPY | -26.08% |
| 2018 Q1 | 98.87 Billion JPY | 222.82% |
| 2018 Q3 | 112.46 Billion JPY | 53.88% |
| 2017 Q3 | 87.93 Billion JPY | 123.34% |
| 2017 FY | 241.78 Billion JPY | 55.13% |
| 2017 Q1 | 194.97 Billion JPY | 416.71% |
| 2017 Q2 | 39.37 Billion JPY | -79.81% |
| 2017 Q4 | -80.49 Billion JPY | -191.54% |
| 2016 Q4 | -61.56 Billion JPY | -211.22% |
| 2016 Q2 | 9.14 Billion JPY | -94.02% |
| 2016 FY | 155.86 Billion JPY | 19.14% |
| 2016 Q1 | 152.93 Billion JPY | 517.26% |
| 2016 Q3 | 55.35 Billion JPY | 505.42% |
| 2015 FY | 130.82 Billion JPY | 201.22% |
| 2015 Q4 | -36.65 Billion JPY | -164.27% |
| 2015 Q3 | 57.03 Billion JPY | -6.34% |
| 2015 Q2 | 60.89 Billion JPY | 22.86% |
| 2015 Q1 | 49.55 Billion JPY | 115.1% |
| 2014 Q4 | -328.3 Billion JPY | -498.64% |
| 2014 FY | -129.25 Billion JPY | -192.81% |
| 2014 Q1 | 63.68 Billion JPY | 311.71% |
| 2014 Q2 | 53 Billion JPY | -16.77% |
| 2014 Q3 | 82.35 Billion JPY | 55.37% |
| 2013 FY | 139.27 Billion JPY | 13.69% |
| 2013 Q3 | 66.78 Billion JPY | 26.73% |
| 2013 Q2 | 52.7 Billion JPY | 10.48% |
| 2013 Q1 | 47.7 Billion JPY | 269.36% |
| 2013 Q4 | -30.08 Billion JPY | -145.04% |
| 2012 FY | 122.5 Billion JPY | -53.78% |
| 2012 Q1 | 216.1 Billion JPY | 158.75% |
| 2012 Q2 | 200.09 Billion JPY | -7.41% |
| 2012 Q4 | -28.16 Billion JPY | 89.39% |
| 2012 Q3 | -265.52 Billion JPY | -232.7% |
| 2011 Q4 | -367.82 Billion JPY | -276.06% |
| 2011 Q3 | 208.91 Billion JPY | 2.75% |
| 2011 FY | 265.02 Billion JPY | -27.8% |
| 2011 Q2 | 203.33 Billion JPY | -7.83% |
| 2011 Q1 | 220.6 Billion JPY | 176.24% |
| 2010 Q3 | 217.18 Billion JPY | -1.17% |
| 2010 FY | 367.08 Billion JPY | -12.64% |
| 2010 Q4 | -289.34 Billion JPY | -233.23% |
| 2010 Q1 | 219.48 Billion JPY | 177.33% |
| 2010 Q2 | 219.76 Billion JPY | 0.13% |
| 2009 Q2 | 236.71 Billion JPY | -2.49% |
| 2009 Q4 | -283.82 Billion JPY | -226.4% |
| 2009 Q3 | 224.54 Billion JPY | -5.14% |
| 2009 FY | 420.21 Billion JPY | 37.11% |
| 2009 Q1 | 242.77 Billion JPY | 181.63% |
| 2008 Q2 | 251.94 Billion JPY | 0.0% |
| 2008 Q4 | -297.42 Billion JPY | -210.76% |
| 2008 Q3 | 268.52 Billion JPY | 6.58% |
| 2008 FY | 306.46 Billion JPY | -27.57% |
| 2007 FY | 423.12 Billion JPY | -7.72% |
| 2006 FY | 458.5 Billion JPY | 13.83% |
| 2005 FY | 402.8 Billion JPY | 4.55% |
| 2004 FY | 385.27 Billion JPY | 3.67% |
| 2003 FY | 371.63 Billion JPY | 19.62% |
| 2002 FY | 310.68 Billion JPY | 10.47% |
| 2001 FY | 281.24 Billion JPY | 24.39% |
| 2000 FY | 226.1 Billion JPY | 31.88% |
| 1999 FY | 171.44 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | -4086.877% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 160.44% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | -24.854% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 109595.118% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | -582.072% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | -2150.342% |
| Eisai Co., Ltd. | 53.4 Billion JPY | -300.829% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -29798.743% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | -1525.845% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | -3589.04% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -10799.949% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 43435.02% |
| Tsumura & Co. | 20.01 Billion JPY | -969.413% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | -5229.226% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | -4150.894% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | -1113.027% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -5448.86% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | -2103.178% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | -3460.203% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 7052.744% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | -5397.56% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 26474.7% |
| MedRx Co., Ltd | -933 Million JPY | 23044.802% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | -4055.192% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 18894.996% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 9132.7% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | -3193.462% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | -1033.512% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 30794.529% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | -1007.418% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | -4784.975% |